全球胃癌診斷市場

至2030年，全球胃癌診斷市場規模將達30億美元

全球胃癌診斷市場規模在 2024 年估計為 24 億美元，預計到 2030 年將達到 30 億美元，2024 年至 2030 年的複合年成長率為 3.5%。試劑和耗材是報告中分析的細分市場之一，預計複合年成長率為 2.8%，在分析期結束時達到 20 億美元。在分析期間內，設備部分的複合年成長率預計為 4.8%。

美國市場規模估計為 6.645 億美元，中國市場預計複合年成長率為 6.3%

預計 2024 年美國胃癌診斷市場價值將達到 6.645 億美元。作為世界第二大經濟體，中國到 2030 年的市場規模預計將達到 5.918 億美元，在 2024-2030 年分析期間的複合年成長率為 6.3%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 1.4% 和 2.6%。在歐洲，德國的複合年成長率預計為 1.9%。

全球胃癌診斷市場—主要趨勢與促進因素摘要

為什麼胃癌診斷的進步對於早期發現和改善預後至關重要？

早期發現胃癌是一項重大挑戰。症狀通常在疾病發展後才會出現，導致預後不良和存活率降低。然而，胃癌診斷技術的進步正在改變這種狀況，使得人們能夠在更早、更容易治療的階段發現疾病。因此，人們越來越重視開發能夠在胃癌發展之前檢測出它的診斷技術。超音波超音波（EUS）和正子斷層掃描（PET）等影像技術的進步極大地提高了我們檢測胃腫瘤和評估其程度的能力。此外，生物標記檢測在診斷過程中變得越來越重要。研究性治療已經確定了與胃癌相關的各種生物標記物，包括 HER2、p53 和 CA19-9，幫助臨床醫生更準確地檢測胃癌並根據分子圖譜制定個人化治療方案。液態切片是一種分析血液樣本中腫瘤 DNA 的非侵入性測試，也是提高診斷能力的突破性方法。這種方法可以提前發現並監測治療結果，而無需進行侵入性手術。這些創新至關重要，因為它們不僅增加了早期發現的機會，而且提高了治癒治療的機會，顯著改善了患者的治療效果和存活率。對早期診斷重要性的認知導致對研發的投入增加，從而推動了胃癌檢測的進一步創新。

科技創新如何改變胃癌診斷？

技術創新在改變胃癌診斷方面發揮關鍵作用，使其更有效率、準確且易於獲取。其中最重要的發展之一是成像技術的進步。將高清攝影機與窄頻成像（NBI）和共聚焦雷射內視鏡（CLE）等先進成像技術相結合，提高了內視鏡在細胞層面觀察胃腫瘤和癌前病變的能力。這些技術可以更早發現異常生長並進行更精確的切片檢查，從而提高診斷結果的準確性。此外，人工智慧 (AI) 和機器學習 (ML) 的出現顯著增強了成像分析能力，使得能夠更快、更準確地識別胃癌。現在可以訓練人工智慧演算法來檢測人眼可能錯過的影像資料中的細微模式，幫助放射科醫生和病理學家做出更快、更準確的診斷。次世代定序（NGS）技術的進步使得對胃癌進行全面的基因分析成為可能，分子診斷也得到了快速發展。這種方法可以為腫瘤突變和基因表現提供有價值的見解，有助於指南標靶治療並改善患者的治療效果。此外，分析血液樣本中循環腫瘤 DNA (ctDNA) 的液態切片技術正在徹底改變非侵入性診斷。該方法提供了一種比傳統切片檢查技術更簡單、侵入性更小的替代方法，預計在最早、最容易治療的階段中檢測出胃癌。這些技術突破不僅提高了胃癌診斷的速度和準確性，也為更個人化的治療方案奠定了基礎。

推動胃癌診斷解決方案需求的關鍵因素有哪些？

胃癌診斷解決方案的需求不斷成長，這受到多種因素的推動，包括全球胃癌發病率的上升、醫療保健基礎設施的進步以及對早期檢測和個人化醫療的日益關注。由於飲食、幽門螺旋桿菌感染和遺傳易感性等因素，預計許多地區的胃癌發病率將會上升，特別是東亞、中歐和拉丁美洲部分地區。隨著世界各地的醫療保健系統認知到早期癌症檢測的重要性，對更先進的診斷技術的需求日益增加。此外，液態切片和內視鏡篩檢等非侵入性和微創診斷技術的日益普及，使得患者和醫療保健專業人員能夠更方便、更經濟地進行胃癌檢測。世界各國政府和醫療機構也在推動改善癌症篩檢計劃，特別是針對高風險族群，這進一步推動了對胃癌診斷的需求。新興市場醫療保健基礎設施的成長也是一個關鍵因素。隨著開發中地區獲得先進的診斷工具，人們更加關注癌症的預防、早期發現和治療。個人化醫療也是市場驅動力之一，腫瘤基因檢測和分子分析已變得十分普遍，以便為每位患者確定最有效的治療策略。此外，隨著社會對胃癌認知的提高，對能夠在胃癌擴散之前及早發現胃癌的診斷藥物的需求也在不斷成長，最終可以改善預後。所有這些因素共同推動了對胃癌診斷解決方案的需求不斷成長。

推動胃癌診斷市場成長的關鍵因素有哪些？

胃癌診斷市場的成長受到多種因素的推動，包括醫學進步、全球醫療保健投資的增加以及對該疾病的認知的提高。隨著胃癌發生率的不斷上升，人們越來越關注能夠顯著改善預後的早期檢測方法，尤其是在高風險地區。早期發現仍然是提高存活率的最重要因素之一，這推動了對先進診斷解決方案的需求激增，這些解決方案可以在疾病發展到後期、更難治療的階段之前識別疾病。分子和基因診斷的快速發展也是一個主要驅動力，為研發和臨床醫生提供了更精確分析腫瘤和為個別患者量身定做治療方案的工具。液態切片作為一種非侵入性診斷工具的引入，比傳統切片檢查提供了更早、更安全的檢測胃癌的方法，進一步改變了現狀。此外，包括人工智慧成像系統和高清內視鏡在內的成像技術的進步，為胃組織提供了更準確、更詳細的評估，從而可以更好地檢測異常生長和早期腫瘤。此外，隨著世界各地醫療保健系統的不斷現代化，這些尖端診斷工具的使用變得越來越普遍，尤其是在新興市場。人們認知到胃癌篩檢的重要性，尤其是對高風險族群的重要性，導致公共和私營部門都增加了對診斷技術的投資。技術發展以及對利用基因和分子數據來個性化治療計劃的日益關注，正在刺激對能​​夠提供更準確和個性化治療方案的診斷的需求。這些因素正在推動技術創新和應用，預計將推動胃癌診斷市場的持續成長，並有可能改善全球患者的治療結果和存活率。

部分

產品類型（試劑及耗材、設備）；疾病類型（腺癌、胃淋巴瘤、其他疾病類型）；最終用戶（醫院、診斷實驗室、影像中心）

受訪公司範例（42家值得關注的公司）

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD（Becton, Dickinson and Company）
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin SpA
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN NV

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地以及進出口（成品和OEM）預測公司競爭地位的變化。這種複雜且多方面的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、降低盈利、重組供應鏈等微觀和宏觀市場動態。

全球產業分析師密切關注世界領先的首席經濟學家（14,949）、智庫（62）和貿易及產業協會（171）的專家意見，以評估生態系統的影響並應對新的市場現實。各主要國家的專家和經濟學家都在關注關稅及其對國家的影響。

全球產業分析師預計，這種動盪將在未來兩到三個月內平息，新的世界秩序將更加明確地建立。全球產業分析師正在即時追蹤這些發展。

2025年4月：談判階段

我們四月份的發布將涵蓋關稅對全球市場整體的影響，並為各地區的市場調整提供指導。我們的預測是基於歷史數據和不斷發展的市場影響因素。

2025年7月：最終關稅調整

免費更新 在各國宣布最終重置後，本公司的客戶將在 7 月收到免費更新。最終更新包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業和領域專家的最具影響力的首席經濟學家，他們共用了全球經濟狀況這一前所未有的模式轉移的影響。我們的 16,491 多份報告中的大多數都遵循這個基於兩階段里程碑的發布計劃。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 比賽

Global Gastric Cancer Diagnostics Market to Reach US$3.0 Billion by 2030

The global market for Gastric Cancer Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$664.5 Million While China is Forecast to Grow at 6.3% CAGR

The Gastric Cancer Diagnostics market in the U.S. is estimated at US$664.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$591.8 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gastric Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Are Advances in Gastric Cancer Diagnostics Crucial for Early Detection and Better Prognosis?

The early detection of gastric cancer is a major challenge, as symptoms often do not appear until the disease has progressed to later stages, leading to poor prognosis and low survival rates. However, advancements in gastric cancer diagnostics are changing the landscape, making it possible to detect the disease at earlier, more treatable stages. As a result, there has been a growing emphasis on developing diagnostic technologies that can identify gastric cancer before it reaches advanced stages. The evolution of imaging techniques, such as endoscopic ultrasound (EUS) and positron emission tomography (PET), has greatly improved the ability to detect gastric tumors and assess their spread. Moreover, biomarker testing is becoming increasingly prominent in the diagnostic process. Researchers have identified a range of biomarkers associated with gastric cancer, including HER2, p53, and CA 19-9, which are helping clinicians to detect the disease more accurately and to personalize treatment plans based on molecular profiles. Liquid biopsy, a non-invasive testing method that analyzes tumor DNA from blood samples, is another breakthrough that is advancing diagnostic capabilities. This approach enables early-stage detection and monitoring of treatment response without the need for invasive procedures. These innovations are crucial as they not only improve the chances of early detection but also offer better chances for curative treatment, significantly enhancing patient outcomes and survival rates. With growing recognition of the importance of early-stage diagnostics, there has been increased investment in research and development, further driving innovation in gastric cancer detection.

How Are Technological Innovations Transforming Gastric Cancer Diagnostics?

Technological innovations are playing a pivotal role in transforming gastric cancer diagnostics, making them more efficient, accurate, and accessible. One of the most significant developments has been the advancement in imaging technologies. Endoscopy, combined with high-definition cameras and advanced imaging techniques like narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), has improved the ability to visualize gastric tumors and precancerous lesions at the cellular level. These technologies allow for earlier detection of abnormal growths and enable more precise biopsies, improving the accuracy of diagnostic results. Furthermore, the advent of artificial intelligence (AI) and machine learning (ML) has significantly enhanced the analysis of diagnostic imaging, enabling more rapid and accurate identification of gastric cancer. AI algorithms can now be trained to detect subtle patterns in imaging data that may be missed by human eyes, helping radiologists and pathologists make faster and more accurate diagnoses. Molecular diagnostics are also seeing rapid growth, with advances in next-generation sequencing (NGS) technology allowing for comprehensive genetic profiling of gastric cancer. This approach provides valuable insights into tumor mutations and gene expression, which can guide targeted therapy and improve patient outcomes. Additionally, liquid biopsy technology, which involves analyzing circulating tumor DNA (ctDNA) from blood samples, is revolutionizing non-invasive diagnostics. This method offers a simpler, less invasive alternative to traditional biopsy procedures and holds promise for detecting gastric cancer in its earliest, most treatable stages. These technological breakthroughs are not only improving the speed and accuracy of gastric cancer diagnosis but are also laying the groundwork for more personalized treatment options.

What Are the Key Factors Driving the Demand for Gastric Cancer Diagnostic Solutions?

The growing demand for gastric cancer diagnostic solutions is driven by several factors, including the rising global incidence of gastric cancer, advancements in healthcare infrastructure, and the increasing focus on early detection and personalized medicine. The incidence of gastric cancer is expected to rise in many regions, particularly in East Asia, Central Europe, and parts of Latin America, due to factors such as diet, Helicobacter pylori infection, and genetic predisposition. As the global healthcare system recognizes the importance of early cancer detection, the demand for more advanced diagnostic technologies is increasing. Moreover, the increasing adoption of non-invasive and minimally invasive diagnostic techniques, such as liquid biopsy and endoscopic screening, is making gastric cancer detection more accessible and cost-effective for patients and healthcare providers alike. Governments and health organizations worldwide are also pushing for improved cancer screening programs, especially in high-risk populations, which is further fueling demand for gastric cancer diagnostics. The growth of healthcare infrastructure in emerging markets is another key factor. As developing regions gain access to advanced diagnostic tools, there is a greater focus on cancer prevention, early detection, and treatment. Personalized medicine is another driver of the market, as genetic testing and molecular profiling of tumors are becoming more common to identify the most effective treatment strategies for each patient. Furthermore, as public awareness of gastric cancer increases, there is greater demand for diagnostics that can detect the disease in its early stages before it spreads, which ultimately leads to better outcomes. All these factors combined are driving the increasing demand for gastric cancer diagnostic solutions.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Diagnostics Market?

The growth of the gastric cancer diagnostics market is driven by a combination of factors related to medical advancements, increasing global healthcare investment, and rising awareness of the disease. As the prevalence of gastric cancer continues to rise, particularly in high-risk regions, there is an increased focus on early detection methods that can significantly improve prognosis. Early detection remains one of the most important factors in improving survival rates, which has led to a surge in demand for advanced diagnostic solutions that can identify the disease before it progresses to later, harder-to-treat stages. The rapid development of molecular and genetic diagnostics is another key driver, as researchers and clinicians now have the tools to more accurately profile tumors and tailor treatments to individual patients. The introduction of liquid biopsy as a non-invasive diagnostic tool is further transforming the landscape by offering a method for detecting gastric cancer earlier and more safely than traditional biopsies. Additionally, advancements in imaging technology, including AI-powered imaging systems and high-definition endoscopy, are providing more accurate and detailed assessments of gastric tissue, allowing for improved detection of abnormal growths and early-stage tumors. Furthermore, as healthcare systems across the globe continue to modernize, especially in emerging markets, access to these cutting-edge diagnostic tools is becoming more widespread. The increased recognition of the importance of gastric cancer screening, particularly in high-risk populations, has driven both public and private investments in diagnostic technologies. In addition to technological developments, the growing focus on personalized treatment plans that leverage genetic and molecular data has spurred the demand for diagnostics that can provide more precise and tailored treatment options. With these factors driving innovation and adoption, the gastric cancer diagnostics market is poised for continued growth, offering the potential for better outcomes and survival rates for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents & Consumables, Instruments); Disease Type (Adenocarcinoma, Gastric Lymphoma, Other Disease Types); End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastric Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Gastric Cancer Worldwide Drives Increased Demand for Advanced Diagnostic Solutions
  • Growing Awareness of Genetic and Lifestyle Factors Fuels Demand for Comprehensive Gastric Cancer Screening
  • Surge in Investment in Non-Invasive Diagnostic Technologies Expands Market Opportunities for Gastric Cancer Detection
  • Advancements in Liquid Biopsy and Molecular Diagnostics Drive Accuracy and Sensitivity in Early Diagnosis
  • Here's How the Integration of AI and Machine Learning in Diagnostic Tools is Enhancing Gastric Cancer Detection
  • Increased Adoption of Endoscopic Screening Methods Boosts Early Detection Rates and Market Growth
  • Growing Role of Biomarkers in Gastric Cancer Diagnostics Strengthens the Business Case for Precision Medicine
  • Rising Demand for Point-of-Care Diagnostics Expands Access to Early Gastric Cancer Detection in Remote Areas
  • Technological Innovations in Imaging and Optical Methods Enhance Diagnostic Precision and Minimize Invasiveness
  • Rising Focus on Multi-Omic Approaches, Including Genomic and Proteomic Profiling, Drives Diagnostic Advancements
  • Expanding Use of Companion Diagnostics for Personalized Treatment Planning in Gastric Cancer Strengthens Market Potential
  • Rising Focus on Early Detection in High-Risk Populations Creates Opportunities for Targeted Screening Solutions
  • Increased Demand for Integrated Healthcare Solutions and Data Analytics Platforms Enhances Gastric Cancer Diagnostic Accuracy
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastric Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Gastric Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diagnostic Imaging Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• JAPAN
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• CHINA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• EUROPE
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• FRANCE
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• GERMANY
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• INDIA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• AFRICA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030

IV. COMPETITION